Viking Therapeutics, Inc. (VKTX) Cash Flow Statement

14Y historyFree accessUpdated daily

Viking Therapeutics, Inc. (VKTX) annual cash flow statement — 14-year operating, investing & financing history

Metric	TTM	Dec'25	Dec'24	Dec'23	Dec'22	Dec'21	Dec'20	Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12

Cash from Operations	-340.33M	-278.69M	-87.79M	-73.38M	-48.4M	-47.59M	-21.78M	-24.75M	-18.75M	-14.76M	-11.07M	-8.73M	-1.59M	-78.23K	-200
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-684.41%	-217.45%	-19.64%	-51.61%	-1.7%	-118.51%	12.02%	-31.98%	-27.09%	-33.3%	-26.8%	-448.66%	-1934.16%	-39017.5%	-
Net Income	-472.33M	-359.64M	-109.96M	-85.89M	-68.87M	-54.99M	-39.49M	-25.78M	-22.06M	-20.58M	-14.73M	-23.4M	-21.88M	-146.25K	-444
Depreciation & Amortization	-6.59M	431K	346K	292K	291K	296K	277K	260K	477K	1.38M	1.94M	1.03M	0	0	0
Stock-Based Compensation	39.81M	40.82M	29.71M	16.75M	8.67M	6.1M	5.82M	3.74M	2.61M	1.45M	1.79M	2.6M	6.26K	4	22
Deferred Taxes	0	0	0	0	0	0	0	0	-392K	-1.28M	-1.79M	-893.5K	0	0	0
Other Non-Cash Items	34.74M	-9.27M	-17.25M	-8.07M	1.32M	3.94M	3.91M	807K	-208K	2.5M	862.62K	11.32M	-1.65M	42.57K	244
Working Capital Changes	64.04M	48.98M	9.36M	3.55M	10.19M	-2.93M	7.72M	-3.78M	823K	1.77M	849.88K	620.32K	21.94M	25.44K	0
Change in Receivables	2.61M	5.08M	1.2M	321K	0	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change in Payables	59.48M	43.44M	2.3M	-1.02M	7.08M	-2.54M	1.55M	1.47M	-508K	263.51K	677.18K	219.24K	190.3K	20.06K	0
Cash from Investing	332.33M	341.39M	-553.37M	-179.09M	54.75M	37.96M	41.57M	7.46M	-265.73M	-1.73M	3.03M	-13.47M	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Investing	291.68M	0	0	0	54.75K	0	0	0	-265.73K	-1.73K	3.03K	-13.47K	0	0	0
Cash from Financing	88.17M	76.44M	612.46M	271.38M	4.16M	6.88M	950K	887K	300.27M	22.4M	10.35M	22.21M	2.17M	257.85K	200
Debt Issued (Net)	0	0	0	0	0	0	0	0	-3.83M	-77K	-94.86K	0	2.5M	260.35K	0
Equity Issued (Net)	2.14M	2.49M	597.09M	269.76M	-8.33M	7.59M	1.25M	1.04M	296.61M	22.35M	11.55M	25.39M	-2	-2.5K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	-6.79M	0	0	0	0	0	-229	-38	-2	-2.5K	0
Other Financing	86.03M	73.95M	15.37M	1.62M	12.49M	-707K	-296K	-151K	7.5M	125.45K	-1.1M	-3.18M	-332.34K	0	200
Net Change in Cash	80.18M	139.13M	-28.84M	18.88M	10.26M	-2.75M	20.74M	-16.4M	15.79M	5.91M	2.31M	12.69K	576.24K	179.62K	0
Free Cash Flow	-340.33M	-278.69M	-87.79M	-73.38M	-48.4M	-47.59M	-21.78M	-24.75M	-18.75M	-14.76M	-11.07M	-8.73M	-1.59M	-78.23K	-200
FCF Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-154%	-217.45%	-19.64%	-51.61%	-1.7%	-118.51%	12.02%	-31.98%	-27.09%	-33.3%	-26.8%	-448.66%	-1934.16%	-39017.5%	-
FCF per Share	-2.94	-2.47	-0.81	-0.78	-0.63	-0.62	-0.30	-0.34	-0.33	-0.57	-0.68	-1.37	-0.37	-0.02	-0.13
FCF Conversion (FCF/Net Income)	0.72x	0.77x	0.80x	0.85x	0.70x	0.87x	0.55x	0.96x	0.85x	0.72x	0.75x	0.37x	0.07x	0.53x	0.45x
Interest Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

VKTX — Frequently Asked Questions

Quick answers to the most common questions about buying VKTX stock.

How much cash does Viking Therapeutics, Inc. (VKTX) generate from operations?

Viking Therapeutics, Inc. (VKTX) generated $-278.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Viking Therapeutics, Inc.'s free cash flow?

Viking Therapeutics, Inc. (VKTX) reported negative free cash flow of $278.7M in 2025, indicating capital requirements exceeded cash from operations.

What is Viking Therapeutics, Inc.'s capital expenditure (CapEx)?

Viking Therapeutics, Inc. (VKTX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.